Minoxidil

Research records

Historical source snapshot. Not freshly verified, not a recommendation. Study findings, community accounts and app defaults are not interchangeable.

Publication suitability · 2026-10-15: Historical reference only; not a clinical verification. Clinical, regulatory, efficacy, safety and dose claims are not independently established by this review.

Minoxidil

An FDA-approved topical medication for pattern hair loss that extends the hair growth phase and increases follicle size.

Evidence category: Regulator / guideline. This describes the source category, not approval or certainty.

Regulatory statement in source: FDA-approved.

Minoxidil is an FDA-approved topical medication for androgenetic alopecia (pattern hair loss) in both men and women. Topical minoxidil was approved by the FDA for male pattern hair loss in 1988 and for female pattern hair loss in 1991. It is available over-the-counter in 2% and 5% solutions and 5% foam formulations in the United States. Minoxidil works by enlarging miniaturized hair follicles, extending the anagen (growth) phase of the hair cycle, and shortening the telogen (resting) phase, thereby decreasing hair loss and increasing hair thickness. It is converted to its active form, minoxidil sulfate, in the scalp by the enzyme SULT1A1. Topical minoxidil has been found safe and effective in meta-analysis with similar efficacy and safety across different concentrations.

Benefits reported in the imported source

• Male and female pattern hair loss with demonstrated efficacy.
• Topical formulation has favorable safety profile with no significant difference across concentrations
• First-line therapy in most clinical scenarios

Risks and limits

• Oral minoxidil (off-label) associated with hypertrichosis (unwanted hair growth)
• Cardiovascular events rare but reported at higher oral doses
• Topical application limited to scalp area

Source bottom line: Minoxidil is an FDA-approved, over-the-counter topical treatment for pattern hair loss with established efficacy and favorable safety profile when used topically.

Uncertainty: Reference information only. Not medical advice.

Study protocols — reports, not instructions

Community and practice descriptions

Accounts of a practice are not evidence of safety or effectiveness. Words such as “standard”, “safe” or “recommended” describe the source account, not verified consensus or this wiki’s advice. Commercial and self-published citations are retained for traceability, not vendor endorsement or independent clinical corroboration.

Pharmacokinetic context

No half-life recorded in this source snapshot. No value has been inferred.

Source references

• DailyMed: minoxidil
• Male and Female Pattern Hair Loss: A Guide to Treatment
• Minoxidil: a comprehensive review
• Minoxidil: Formulation, Dosage & Side-Effects